Compare · GNOM vs JHB
GNOM vs JHB
Side-by-side comparison of Global X Genomics & Biotechnology ETF (GNOM) and Nuveen High Income November 2021 Target Term Fund (JHB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GNOM and JHB operate in n/a (n/a), so they compete in similar markets.
- JHB carries a market cap of $525.4M.
Global X Genomics & Biotechnology ETF
The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
Latest GNOM
No recent items for Global X Genomics & Biotechnology ETF.
Latest JHB
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund
- Nuveen Corporate Income November 2021 Target Term Fund Announces Termination and Liquidation
- SEC Form 25-NSE filed by Nuveen High Income November 2021 Target Term Fund
- Nuveen Corporate Income November 2021 Target Term Fund Announces Liquidation Details
- SEC Form N-CSRS filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form N-PX filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form 3 filed by Lancellotta Amy B.R.
- Nuveen Corporate Income November 2021 Target Term Fund Announces Wind-Up Period
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund